Skip to Content

'
Sunil Krishnan, MD, FACP

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

As an Associate Professor on the gastrointestinal cancer service of the Department of Radiation Oncology, Dr. Krishnan is actively involved in patient care and clinical trials. Also, as the Director of Translational Research for this service, he has basic and translational science laboratory interests. His clinical effort is directed towards developing novel therapies for patients with gastrointestinal tumors. He is the principal investigator of several clinical trials focusing on radiation sensitization strategies for these tumors, especially liver, pancreatic and rectal cancers. His laboratory research interests include: 1) understanding the role of dietary botanicals as radiation modifying agents in rectal and pancreatic cancer and translating these findings into new treatment options; 2) identifying means to sensitize tumors to radiation therapy using metallic nanoparticles to generate radiation dose-enhancement and/or hyperthermia and 3) developing nanoparticle-based molecular imaging probes to facilitate image-guided therapy.

Education & Training

Degree-Granting Education

1993 Christian Medical College, Vellore, Tamil Nadu, India, MBBS, Medicine

Postgraduate Training

3/2000-3/2004 Clinical Residency, Radiation Oncology, Mayo Clinic, Rochester, MN, Dr. Ivy A. Petersen
1/1997-1/2000 Clinical Residency, Internal Medicine, Penn State Geisinger Medical Center, Danville, PA, Dr. Robert Palinkas
1/1994-1/1995 Clinical Internship, Christian Medical College and Hospital, Vellore, Tamil Nadu, India, Dr. Bhooshanam V. Moses

Board Certifications

6/2005 American Board of Radiology (Radiation Oncology)
2000 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 6/2004-9/2009

Administrative Appointments/Responsibilities

Director, Center of Radiation Oncology Research, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2013-present
Director, Gastrointestinal Translational Research, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-present

Honors and Awards

2005 Translational Research Symposium Travel Grant, American Society for Therapeutic and Radiation Oncology
2003 Roentgen Resident/Fellow Research Award, Radiological Society of North America
2003 Travel Award, Radiation Therapy Oncology Group
2002 AMA Foundation Leadership Award, American Medical Association
2002 Mayo Brother's Distinguished Fellowship Award, Mayo Clinic Graduate School of Medicine
2002 Robert D. and Alma Moreton Fellowship, Mayo Clinic Graduate School of Medicine
1996 J. N. Tata Endowment Scholarship, J. N. Tata Endowment
1993 Undergraduate Research Prize, Christian Medical College, Vellore, India
1992 National Junior Research Scholarship, Indian Council for Medical Research

Professional Memberships

ASCO
Member, 2004-present
ASTRO
Chair, GI Scientific Program Committee, 2006-2007
ASTRO
Member, 2004-present
ASTRO
Scientific Program Subcommittee, 2004-2006
Harris County Medical Society
Member, 2004-present
RTOG
Co-Chair, GI Translation Research Committee, 2006-present
RTOG
Steering Committee, Translational Research Program, 2006
RTOG
Member, 2004-present
Texas Medical Association
Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric Bleeding After Radiation Therapy for Intrahepatic Cholangiocarcinoma. Prac Radiat Oncol. In Press.
2. Taddei PJ, Howell RM, Krishnan S, Scarboro SB, Mirkovic D, Newhauser WD. Risk of second malignant neoplasm following proton versus intensity modulated photon radiotherapy for hepatocellular carcinoma. Phys Med Biol. In Press.
3. Tzeng C-W, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane C, Wolff RA, Varadhachary GR, Pisters P, Aloia TA, Vauthey J-N, Haynes RJ, Fleming JB, Katz MH. Serum CA 19-9 Represents a Marker of Response to Neoadjuvant Therapy in Patients with Borderline Resectable Pancreatic Cancer. HPB. In Press.
4. Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME, Crane CH. Duodenal Toxicity after Fractionated Chemoradiation for Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 85(3):e143-149, 3/1/2013. e-Pub 11/29/2012. PMID: 23200173.
5. Liang S, Bian X, Ma J, Arogunjo M, Deorukhkar AA, Krishnan S, Xie H. Development and validation of a sensitive LC/MS/MS method for the determination of γ-tocotrienol in rat plasma: application to pharmacokinetic studies. Biomed Chromatogr 27(1):58-66, 1/2013. e-Pub 4/20/2012. PMID: 22522964.
6. Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, Diagaradjane P, Wei C, Baladandayuthapani V, Krishnan S, Guha S, Aggarwal BB. Ursolic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in an Orthotopic Nude Mouse Model by Targeting Multiple Cell Signaling Pathways: Chemosensitization with Capecitabine. Clin Cancer Res 18(18):4942-4953, 9/15/2012. e-Pub 7/25/2012. PMID: 22832932.
7. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 7/2012. e-Pub 1/10/2012. PMCID: PMC3355215.
8. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-586, 6/2012. e-Pub 12/2011. PMID: 22137021.
9. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer 130(9):2176-2184, 5/2012. e-Pub 9/2011. PMCID: PMC3246525.
10. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. J Clin Oncol 30(15):1770-1776, 5/2012. e-Pub 4/2012. PMID: 22493423.
11. Puvanakrishnan P, Diagaradjane P, Kazmi SM, Dunn AK, Krishnan S, Tunnell JW. Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers Surg Med 44(4):310-317, 4/2012. e-Pub 3/2012. PMID: 22415634.
12. Kelly P, Das P, Varadhachary GR, Fontanilla HP, Krishnan S, Delclos ME, Jhingran A, Eifel PJ, Crane CH. Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis. Int J Radiat Oncol Biol Phys 82(5):2012-2017, 4/2012. e-Pub 6/2011. PMID: 21640510.
13. Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 12(1). e-Pub 3/27/2012. PMID: 22452810.
14. Puvanakrishnan P, Park J, Chatterjee D, Krishnan S, Tunnell JW. In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomedicine 7:1251-1258, 2012. e-Pub 3/6/2012. PMCID: PMC3299576.
15. Botros M, Chang K, Miller R, Krishnan S, Iott M. Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiol Oncol 46(1):23-27, 2012.
16. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-1198, 11/2011. e-Pub 7/2011. PMID: 21793641.
17. Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol 21(4):278-286, 10/2011. PMID: 21939857.
18. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-3899, 10/2011. e-Pub 9/2011. PMCID: PMC3189091.
19. Ryan JL, Krishnan S, Movsas B, Coleman CN, Vikram B, Yoo SS. Decreasing the Adverse Effects of Cancer Therapy: An NCI Workshop on the Preclinical Development of Radiation Injury Mitigators/Protectors. Radiat Res. e-Pub 9/2011.
20. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. e-Pub 9/2011. PMID: 21935918.
21. Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 117(16):3713-3722, 8/2011. e-Pub 2/2011. PMID: 21328329.
22. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-3043, 8/2011. e-Pub 6/2011. PMID: 21709185.
23. Kaur P, Hurwitz MD, Krishnan S, Asea A. Combined hyperthermia and radiotherapy for the eradication of cancer. Cancers 3:3799-3823, 2011.
24. Xie H, Diagaradjane P, Deorukhkar AA, Goins B, Bao A, Phillips WT, Wang Z, Schwartz J, Krishnan S. Integrin avß3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine 6:259-269, 2011. e-Pub 1/2011. PMCID: PMC3058535.
25. Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 6:63, 2011. e-Pub 6/2011. PMCID: PMC3121606.
26. Chatterjee DK, Diagardjane P, Krishnan S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther Deliv 2(8):1001–1014, 2011.
27. Sharma D, Sandur SK, Rashmi R, Maurya DK, Suryavanshi S, Checker R, Krishnan S, Sainis KB. Differential activation of NF-kappaB and nitric oxide in lymphocytes regulates in vitro and in vivo radiosensitivity. Mutat Res 703(2):149-57, 12/2010. e-Pub 8/2010. PMCID: PMC3071568.
28. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 80(12):1904-14, 12/2010. e-Pub 6/2010. PMCID: PMC3090731.
29. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2(55):55ra79, 10/2010. PMID: 20980696.
30. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar AA, Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. {gamma}-Tocotrienol Inhibits Pancreatic Tumors and Sensitizes Them to Gemcitabine Treatment by Modulating the Inflammatory Microenvironment. Cancer Res. e-Pub 9/2010. PMID: 20864511.
31. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. Int J Hyperthermia. e-Pub 9/2010. PMID: 20858069.
32. Checker R, Sharma D, Sandur SK, Subrahmanyam G, Krishnan S, Poduval TB, Sainis KB. Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. J Cell Biochem 110(5):1082-1093, 8/2010. PMID: 20564204.
33. Diagaradjane P, Deorukhkar A, Gelovani JG, Maru DM, Krishnan S. Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano 4(7):4131-4141, 7/2010. PMID: 20586481.
34. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127(2):257-268, 7/2010. e-Pub 11/2009. PMID: 19908231.
35. Deorukhkar A, Shentu S, Park HC, Diagaradjane P, Puduvalli V, Aggarwal B, Guha S, Krishnan S. Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells. Pancreas. e-Pub 6/2010. PMID: 20531243.
36. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol. e-Pub 6/2010. PMID: 20552409.
37. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12(5):313-320, 6/2010. PMID: 20590905.
38. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Bagherazadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S. A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 9(5):1136-1146, 5/2010. e-Pub 5/2010. PMCID: PMC2905628.
39. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol 77(5):818-827, 5/2010. e-Pub 1/2010. PMCID: PMC2872971.
40. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients with Prior Pelvic Irradiation. Int J Radiat Oncol Biol Phys 77(1):60-65, 5/2010. e-Pub 8/2009. PMID: 19695792.
41. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, Aggarwal BB. Sesamin manifests chemopreventive effects through the suppression of NF-kappaB-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 8(5):751-761, 5/2010. e-Pub 5/2010. PMCID: PMC2895997.
42. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 76(3):824-830, 3/2010. e-Pub 5/2009. PMID: 19464823.
43. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 116(4):822-829, 2/2010. PMID: 20041481.
44. Jones BL, Krishnan S, Cho SH. Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys 37(7):3809-3816, 2010.
45. Park J, Estrada A, Schwartz JA, Diagaradjane P, Krishnan S, Payne JD, Dunn AK, Tunnell JW. Intra-organ biodistribution of gold nanoparticles using intrinsic two photon induced photoluminescence. Lasers Surg Med 42(7):630-639, 2010.
46. Kunnumakkara AB, Diagaradjane P, Anand P, Kuzhuvelil HB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, Aggarwal BB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125(9):2187-2197, 11/2009. PMID: 19623659.
47. Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CH. Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer with Para-aortic Nodal Involvement. Int J Radiat Oncol Biol Phys 75(3):791-794, 11/2009. e-Pub 2/2009. PMID: 19231109.
48. Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated with Preoperative Chemoradiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys 75(3):775-781, 11/2009. e-Pub 2/2009. PMID: 19231100.
49. Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, Delclos ME, Feig BW. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol:441-447, 10/2009. e-Pub 10/2009. PMID: 19847569.
50. Cheong SK, Krishnan S, Cho SH. Modeling of plasmonic heating from individual gold nanoshells for near-infrared laser-induced thermal therapy. Med Phys 36(10):4664-4671, 10/2009. PMID: 19928098.
51. Cho SH, Jones BL, Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol 54(16):4889-4905, 8/2009. e-Pub 7/2009. PMID: 19636084.
52. Briere TM, Beddar S, Balter P, Murthy R, Gupta S, Nelson C, Starkschall G, Gillin MT, Krishnan S. Respiratory gating with EPID-based verification: the MDACC experience. Phys Med Biol 54(11):3379-3391, 6/2009. e-Pub 5/2009. PMID: 19436104.
53. Sharma D, Kumar SS, Checker R, Raghu R, Khanam S, Krishnan S, Sainis KB. Spatial distribution, kinetics, signaling and cytokine production during homeostasis driven proliferation of CD4+ T cells. Mol Immunol 46(11-12). e-Pub 5/2009. PMID: 19447493.
54. Katz MHG, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey J-N, Abdalla EK, Lee JE, Pisters PWT, Evans DB.. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4). e-Pub 2/5/2009. PMID: 19194760.
55. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Janjan NA, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors and clinical course. Int J Radiat Oncol Biol Phys 74(3). e-Pub 1/2009. PMID: 19147305.
56. Badgwell B, Yao J, Bose D, Oiao W, Krishnan S, Pisters P, Feig B, Mansfield P.. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 16(1):42-50, 2009. e-Pub 11/2008. PMID: 18985270.
57. Taddei PJ, Krishnan S, Mirkovic D, Yepes P, Newhauser WD. Effective dose from stray radiation for a patient receiving proton therapy for liver cancer. AIP Conf. Proc. 1099:445-449, 2009.
58. Maru DM, Luthra R, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Correa A, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma is associated with poor overall survival. Cancer 115(7):1576-1585, 2009. PMID: 19156915.
59. Puvanakrishnan P, Park J, Diagaradjane P, Schwartz JA, Coleman CL, Gill-Sharp KL, Sang KL, Payne JD, Krishnan S, Tunnell JW. NIR narrow band imaging of gold/silica nanoshells in tumors. J Biomed Opt 14(2):024044, 2009. PMID: 19405722.
60. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett C, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55, 2009. PMCID: PMC2787526.
61. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, Aggarwal BB. Modification of the cysteine residues in IκBα kinase and NF-kB (p65) by xanthohumol leads to suppression of NF-κB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood. e-Pub 10/2008.
62. Wang H, Krishnan S, Wang X, Beddar AS, Briere TM, Crane CH, Mohan R, Dong L. Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method. Int J Radiat Oncol Biol Phys 72(1):201-209, 9/2008. PMID: 18722271.
63. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 71(3):741-747, 7/2008. e-Pub 12/2007. PMID: 18164837.
64. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, Krishnan S. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 14(7)(7):2128-2136, 4/2008. PMID: 18381954.
65. Diagaradjane P, Orenstein-Cardona JM, E Colón-Casasnovas N, Deorukhkar A, Shentu S, Kuno N, Schwartz DL, Gelovani JG, Krishnan S. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 14(3):731-741, 2/2008. PMID: 18245533.
66. Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, Szklaruk J, Krishnan S. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol 87(3):445-448, 2008. e-Pub 1/2008. PMID: 18194819.
67. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy F, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton R, Rowland K, Mischel P, Yong WH, Scheithauer B, Schiff D, Giannini C, Buckner J. A North Central Cancer Treatment Group phase I/II trial (N0177) of erlotinib and temozolomide combined with radiation therapy in the treatment of newly-diagnosed glioblastoma multiforme. J Clin Oncol 26(34):5603-5609, 2008.
68. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71(1):167-172, 2008. PMID: 18406886.
69. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 47(3):421-427, 2008. PMID: 17899453.
70. Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, Pisters PW, Feig B, Mansfield P.. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol 15(10):2684-2691, 2008. e-Pub 7/2008. PMID: 18649106.
71. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 19(5):1071-1077, 2008. PMID: 18425360.
72. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Thomas MB, Brown T, Curley S, Evans D, Abdalla EK, Delclos M, Das P, Krishnan S, Wistuba II, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 15(11):3147-3156, 2008. e-Pub 2008. PMID: 18754070.
73. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, Aggarwal BB. Modification of the cysteine residues in IB kinase and NF-B (p65) by xanthohumol leads to suppression of NF-kappa B-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113(9):2003-2013, 2008.
74. Diagaradjane P, Shetty A, Wang JC, Elliott AM, Schwartz J, Shentu S, Park HC, Deorukhkar A, Stafford RJ, Cho SH, Tunnell JW, Hazle JD, Krishnan S. Modulation of in Vivo Tumor Radiation Response via Gold Nanoshell-Mediated Vascular-Focused Hyperthermia: Characterizing an Integrated Antihypoxic and Localized Vascular Disrupting Targeting Strategy. Nano Lett 8(5):1492-1500, 2008. PMID: 18412402.
75. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty A, Logsdon C, Aggarwal BB, Krishnan S, Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 68(15):6100-6108, 2008. PMID: 18676832.
76. Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das P. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 71(4):1175-1180, 2008. e-Pub 1/2008. PMID: 18207667.
77. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Tamm EP, Wang H, Lee JE, Pisters PWT, Vauthey J-N, Abdalla E, Lee JH, Ho L, Staerkel GA, Bhosale PR, Ross WA, Krishnan S, Xiong H, Das P, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-3495, 2008. PMID: 18640929.
78. Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane CH, Gillin M, Mohan R, Beddar S. Proton Radiotherapy for Liver Tumors: Dosimetric Advantages over Photon Plans. Med Dosim 33(4):259-267, 2008. PMID: 18973852.
79. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM, Crane CH, Mornex F. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 15(4):1015-1024, 2008. e-Pub 1/2008. PMID: 18236114.
80. Maru DM, Khurana H, Rashid A, Correa A, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32(9):1404-1411, 2008. PMID: 18670347.
81. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of Vater. Int J Radiat Oncol Biol Phys 70(3):735-743, 2008. e-Pub 11/2007. PMID: 17980502.
82. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14(8)(8):2476-2483, 2008. PMID: 18413840.
83. Krishnan S*, Deorukhkar A*, Sethi G, Aggarwal BB. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 16(11):1753-1773, 2007.
84. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Janjan NA, Krishnan S, Crane CH. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res 1:44-48, 2007.
85. Beddar AS, Kainz K, Briere TM, Tsunashima Y, Pan T, Prado K, Mohan R, Gillin M, Krishnan S. Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. Int J Radiat Oncol Biol Phys 67(2):630-638, 2007. PMID: 17236980.
86. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani JG, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model pancreatic cancer through suppression of proliferation, angiogenesis and inhibition of NF-kB-regulated gene products. Cancer Res 67(8):3853-3861, 2007.
87. Krishnan S, Briere TM, Dong L, Murthy R, Ng C, Balter P, Mohan R, Gillin MT, Beddar AS. Daily targeting of liver tumors: Screening patients with a mock treatment and using a combination of internal and external fiducials for image-guided respiratory-gated radiotherapy. Med Phys 34(12):4591-4593, 2007.
88. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Choen AM, Censullo M. Gastrointestinal ulceration following hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 18(4):553-561, 2007.
89. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuzimab or bevacizumab. J Vasc Interv Radiol 18(12):1588-1591, 2007.
90. Zaman RT, Diagaradjane P, Wang J, Swartz J, Gill-Sharp K, Rajaram N, Payne DJ, Krishnan S, Tunnell JW. In vivo detection of gold nanoshells in tumors using diffuse optical spectroscopy. IEEE J Sel Top Quant Elec 13(6):1715-1720, 2007.
91. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects locally advanced unresectable pancreatic cancer patients for optimal benefit from consolidative chemoradiation therapy. Cancer 110(1):47-55, 2007.
92. Krishnan S, Goble J, Frederick L, James CD, Uhm J, Babovic-Vuksanovic D. Inhibitory effect of pirfenidone on glioblastoma cell lines: implications for treatment of neurofibromatosis. J Appl Sci 7(1):58-68, 2007.
93. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 109(9):1750-1755, 2007.
94. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH. Predictors of tumor response and downstaging in patients treated with preoperative chemoradiation for rectal cancer. Cancer 109:1750-1755, 2007.
95. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102(30):580-592, 2007.
96. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy and improved survival for patients with node-positive ampullary carcinoma. Int J Radiat Oncol Biol Phys 66(2):514-519, 2006.
97. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 29(3):219-224, 2006. PMID: 16755173.
98. Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 1(1):41, 2006.
99. Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, Das P, Delclos ME, Janjan NA, Crane CH. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol 29(6):562-567, 2006. PMID: 17148992.
100. Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC, Buckner JC. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group Protocol N0177. Int J Radiat Oncol Biol Phys 65(4):1192-1199, 2006. PMID: 16626884.
101. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66(3):762-771, 2006. PMID: 17011451.
102. Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 66(5):1378-1383, 2006. PMID: 17056196.
103. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107(11):2589-2596, 2006. PMID: 17083124.
104. Beddar AS, Krishnan S, Briere TM, Wang X, Delclos ME, Ballo MT, Das P, Gould S, Horton JL, Crane CH. The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators. Radiother Oncol 78(2):207-212, 2006. PMID: 16376445.

Editorials

1. Krishnan S, Chang G. Specific KRAS mutations and rectal cancer response to chemoradiation - are we closer to personalization of therapy? Annals Surg Oncol. In Press.
2. Krishnan S, Ahmad M. Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them? J Gastrointest Oncol 4(4):337-9, 12/2013. PMCID: PMC3819774.

Book Chapters

1. Krishnan S, Suresh D, Foote RL. Radiation treatment of endocrine tumors. In: Endocrine Pathology - differential diagnosis and molecular advances, 2nd. Ed(s) RV Lloyd. Humana Press: Totowa, N.J., 567-580, 2010.
2. Diagaradjane P, Mohindra P, Krishnan S. Theranostic applications of gold nanoparticles in cancer. In: Nanoplatform-Based Molecular Imaging. Ed(s) Xiaoyuan Chen. John Wiley & Sons, 639-657, 2010.
3. Janjan NA, Delclos ME, Crane CH, Krishnan S, Das P. The colon and rectum. In: Radiation Oncology, 9th. Ed(s) Cox JD, Ang KK. Elsevier: Philadelphia, PA, 560-605, 2009.
4. Krishnan S, Das P, Crane CH. The liver and biliary system. In: Radiation Oncology, 9th. Ed(s) JC Cox, KK Ang. Elsevier: Philadelphia, 534-559, 2009.
5. Crane CH, Janjan NA, Krishnan S. The stomach and small intestine. In: Radiation Oncology, 9th. Ed(s) JC Cox, KK Ang. Elsevier: Philadelphia, 2009.
6. Krishnan S, Rana V, Crane CH. Combining targeted biological agents with radiotherapy: current status and future directions. In: Targeted therapies in pancreatic cancer. Ed(s) WJ Small. Demos Medical Publishing, 163-184, 2008.
7. Jagetia GC, Krishnan S, Aggarwal BB. Natural agents that can sensitize tumor cells to chemotherapy and radiation therapy. In: Cancer Drug Discovery and Development. Ed(s) B Bonavida. Humana Press: Totowa, NJ, 211-242, 2008.
8. Janjan N, Mahajan A, Chang EL, McCutcheon I, Lin E, Das P, Krishnan S, Chow E. Spinal cord compression. In: Prognosis in Advanced Cancer. Ed(s) P Glare, NA Christakis. Oxford University Press: Oxford, UK, 329-344, 2008.
9. Janjan N, Krishnan S, Das P, Gould MS, Zampieri J, Crane C, Delclos M, Cleeland C, Lutz ST, Chow E. Palliative radiation therapy techniques. In: Cancer Pain Management. Ed(s) MJ Fisch, AW Burton. McGraw Hill: New York, NY, 271-293, 2007.
10. Krishnan S, Foote RL. Radiation treatment of endocrine tumors. In: Endocrine Pathology – differential diagnosis and molecular advances, 1st. Ed(s) Lloyd RV, 399-408, 2004.

Grant & Contract Support

Title: Radiation Dose Enhancement Using Gold Nanoparticles
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2012 - 7/31/2015
 
Title: Tumor-specific prostate brachytherapy using bioconjugated gold nanorods and Yb-169 source
Funding Source: Department of Defense (DOD)
Role: Principal Investigator-MDACC
Principal Investigator: Sang Cho
Duration: 7/1/2012
 
Title: Towards Clinical Translation of Nanoparticle-based Radiosensitization
Funding Source: University of Texas MD Anderson Cancer Center
Role: Principal Investigator
Duration: 2/1/2012 - 1/31/2014
 
Title: The radiosensitization of tumor cells and the radioprotection of normal tissue by tocotrienols
Funding Source: Malaysian Palm Oil Board
Role: Principal Investigator
Duration: 9/24/2010 - 9/23/2013
 
Title: Preclinical platform for theranostic nanoparticles in pancreatic cancer
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Halas
Duration: 9/1/2010 - 8/31/2015
 
Title: Multimodal image guided interstitial laser therapy with magnetofluorescent nanostructures
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Joshi
Duration: 9/1/2010 - 6/15/2013
 
Title: Integrated imaging and photothermal ablation of pancreatic cancer resection margins using targeted gold nanoshells
Funding Source: NCI
Role: Principal Investigator
Duration: 7/15/2010 - 6/30/2013
 
Title: Targeting inducible radioresistance in rectal cancer
Funding Source: The University of Texas MD Anderson Cancer Center
Role: Principal Investigator
Duration: 7/1/2010 - 9/30/2011
 
Title: Optimizing the combination of gold nanoparticles and radiation therapy
Funding Source: University of Texas Health Science Center/NIH
Role: Principal Investigator
Duration: 7/1/2009 - 6/30/2012
 
Title: Biological role of neutrophil gelatinase associated lipocalin in pancreatic cancer
Funding Source: The University of Texas MD Anderson Cancer Center
Role: Collaborator
Principal Investigator: Sushovan Guha
Duration: 7/1/2009 - 6/30/2010
 
Title: Phase I study of the combination of vorinostat and radiation therapy for the treatment of locally advanced pancreatic cancer
Funding Source: Merck
Role: Principal Investigator
Duration: 11/3/2008 - 11/30/2010
 
Title: Targeting inducible radioresistance using curcumin in rectal cancer
Funding Source: Gateway for Cancer Research
Role: Principal Investigator
Duration: 5/15/2008 - 4/15/2011
 
Title: Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib and capecitabine for locally advanced pancreatic cancer
Funding Source: Genentech
Role: Principal Investigator
Duration: 4/1/2008 - 3/31/2011
 
Title: Metal nanoparticle-mediated imaging, targeting, and treatment of cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: James Tunnell
Duration: 3/1/2008 - 2/28/2014
 
Title: Imaging tumor vasculature in living subjects during and after radiotherapy using near infrared quantum dots
Funding Source: The University of Texas MD Anderson Cancer Center
Role: Principal Investigator
Duration: 9/5/2007 - 9/5/2009
 
Title: In vivo quantitative optical tomography of EGFR-targeted quantum dots
Funding Source: University of Texas Center for Biomedical Engineering
Role: Co-Investigator
Principal Investigator: James Tunnell
Duration: 1/1/2007 - 12/31/2007
 
Title: Phase I study of proton radiotherapy and bevacizumab for primary liver tumors
Funding Source: Genentech
Role: Principal Investigator
Duration: 10/27/2006 - 9/2/2010
 
Title: Vascular endothelial growth factor, its receptors and neuropilin expression in pancreatic cancer
Funding Source: Radiation Therapy Oncology Group
Role: Principal Investigator
Duration: 3/1/2006 - 2/28/2006
 
Title: Thermoradiotherapy-Development and validation of a new paradigm in cancer therapeutics
Funding Source: University of Texas Center for Biomedical Engineering
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2006

Last updated: 2/6/2014